Special Issue

Current Research on Immunotherapy for Glioblastoma

Message from the Guest Editor

The poor prognosis of unresectable tumors necessitates research into new therapeutic options and changes in standard treatments. Cancer immunosurveillance focuses on overcoming the immunoresistance of tumor cells to promote cancer eradication. GBM, a “cold tumor” in the immune system, requires a better understanding of effective immunotherapy. This Special Issue aims to cover trials on immunotherapeutic approaches, including immune checkpoint inhibitors, tumor vaccines, and CAR T-cell therapies, and to provide insight into resistance mechanisms and the relationship between radiotherapy and the immune system. Targeting single antigens or immune checkpoint molecules may not be effective due to tumor heterogeneity. CAR T therapies now target multiple antigenic targets simultaneously, and peptide/DC vaccines use the entire tumor lysate instead of a single antigen. Bispecific T-cell engagers (BiTEs) are proposed as a possible solution to overcome antigen escape mechanisms. Personalized immune-based treatments like neoantigen-based vaccines are under clinical evaluation, with combinatorial therapy being crucial for optimal results.

Guest Editor

Dr. Markella Zannikou
Feinberg School of Medicine, Northwestern University, 303 East Superior Ave., Chicago, IL 60611, USA

Deadline for manuscript submissions

31 March 2026

Cells

an Open Access Journal by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed

mdpi.com/si/222993

Cells
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

mdpi.com/journal/cells

Cells

an Open Access Journal by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed

mdpi.com/journal/cells

About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Dr. Alexander E. Kalyuzhny
Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE, Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch
Biotech Research & Innovation Centre, The University of Copenhagen, Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).